Why Did MO, GILD, XOM Stocks Surge To 52-Week Highs Last Week?

What happened

Altria, Gilead Sciences and ExxonMobil reached fresh 52-week highs on Friday after strong third-quarter results, improved earnings outlooks and higher shareholder returns lifted investor confidence. The article attributes support to tobacco pricing, HIV drug sales and refining margins, and reports respective share gains of 1%, 3% and 2%.

Confirmed

Global impact / market context

The reported results point to different business drivers: tobacco pricing and an improved forecast helped Altria, HIV drug sales supported Gilead, and refining margins aided ExxonMobil. If those drivers persist, they could support revenue or profit per sale and make higher shareholder returns more affordable.

Analyst inference

The article links all three stocks’ highs to company-specific results and outlooks, rather than describing a broad market move. For Altria, it also notes weakness in traditional cigarette sales, showing that stronger pricing and forecasts may coexist with pressure on an important part of its business.

Analyst inference

What to watch

1. Check whether Altria delivers its raised 2026 adjusted earnings forecast of $5.66–$5.74 per share; actual results below that range could weaken the outlook supporting its shares. Analyst inference
2. Watch whether tobacco pricing continues to offset weakness in traditional cigarette sales, which Morgan Stanley cited when it maintained an Equal Weight rating on Altria. Analyst inference
3. The article reports higher HIV drug sales for Gilead and improved refining margins for ExxonMobil, but the supplied text gives no further company-specific figures or outlook details. Confirmed

Evidence

• stocktwits.com